BMPR2 and heritable pulmonary arterial hypertension: Therefore, while further analysis of endogenous BMPR2 mutant product folding and signaling defects in HPAH patients will have to be performed to determine which patients might benefit from this therapy, our data suggest an additional disease modifying therapy that may benefit a subset of HPAH patients with NMD negative BMPR2 mutations.